公开(公告)号：WO2009005673A1

公开(公告)日：2009-01-08

申请号：PCT/US2008/007920

申请日：2008-06-25

Applicant: SCHERING CORPORATION ,  WANG, Yan ,  PACHTER, Jonathan, A. ,  HAILEY, Judith, Anne ,  BRAMS, Peter ,  WILLIAMS, Denise ,  SRINIVASAN, Mohan ,  FEINGERSH, Mary, Diane

Inventor： WANG, Yan ,  PACHTER, Jonathan, A. ,  HAILEY, Judith, Anne ,  BRAMS, Peter ,  WILLIAMS, Denise ,  SRINIVASAN, Mohan ,  FEINGERSH, Mary, Diane

IPC: C07K16/38 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: Abstract of the Invention The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.

Abstract translation: 发明概述本发明部分涉及抗IGF1R抗体及其抗原结合组合物及其使用方法。 例如，涵盖治疗诸如癌症的医学病症的方法。

公开(公告)号：WO2008070344A3

公开(公告)日：2008-11-20

申请号：PCT/US2007082647

申请日：2007-10-26

Applicant: LPATH THERAPEUTICS INC ,  SABBADINI ROGER A ,  GARLAND WILLIAM A ,  HANSEN GENEVIEVE ,  JONES STEVEN TARRAN ,  WILLIAMS DAVID GARETH

Inventor： SABBADINI ROGER A ,  GARLAND WILLIAM A ,  HANSEN GENEVIEVE ,  JONES STEVEN TARRAN ,  WILLIAMS DAVID GARETH

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K16/18 ,  C07K16/38 ,  C12N5/10 ,  C12N5/12 ,  C12N15/00 ,  C12P21/08 ,  G01N33/53

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

Abstract: The present invention relates to anti-SIP agents, for example, humanized monoclonal antibodies, and their uses for detection of SIP or for treatment of diseases and conditions associated with SIP.

Abstract translation: 本发明涉及抗SIP剂，例如人源化单克隆抗体，以及它们用于检测SIP或用于治疗与SIP相关的疾病和病症的用途。

公开(公告)号：WO2008052737A3

公开(公告)日：2008-05-08

申请号：PCT/EP2007/009389

申请日：2007-10-30

Applicant: ROCHE DIAGNOSTICS GMBH ,  F. HOFFMANN-LA ROCHE AG

Inventor： SIGLER, Gerald ,  GHOSHAL, Mitali ,  HUI, Raymond ,  SORIANO, Glenda

IPC: C07D213/42 ,  C07D239/10 ,  C07D265/18 ,  C07K16/38 ,  A61K31/513 ,  A61K31/536 ,  A61P31/18

Abstract: HIV protease inhibitor analogs and non-nucleoside reverse transcriptase inhibitor analogs are provided that are immunochemically equivalent to the parent compound. These analog compounds are useful as calibrators and positive controls in assays for determining HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in samples. Methods for preparing calibration curves using the analogs and test kits comprising the analogs are also provided.

公开(公告)号：WO2005010205A3

公开(公告)日：2005-10-13

申请号：PCT/IB2004002468

申请日：2004-07-19

Applicant: PHARMACIA CORP ,  TORTORELLA MICKEY ,  ARNER ELIZABETH ,  MALFAIT ANNE-MARIE

Inventor： TORTORELLA MICKEY ,  ARNER ELIZABETH ,  MALFAIT ANNE-MARIE

IPC: A61K38/00 ,  C07H21/04 ,  C07K5/103 ,  C07K14/81 ,  C07K16/40 ,  C12N9/64 ,  C12Q1/37 ,  G01N33/53 ,  A61P19/02 ,  C07K16/38 ,  G01N33/68

CPC classification number: C07K14/8146 ,  A61K38/00 ,  C07K5/1008 ,  C07K5/1013 ,  C07K14/8107 ,  C12Q1/37 ,  G01N2333/96425 ,  G01N2333/96486 ,  G01N2500/02 ,  G01N2500/10

Abstract: Biomarkers for detecting aggrecanas-1 and/or aggrecanase-2 activity are disclosed. The biomarkers are specific peptide fragments of alpha2 macroglobulin.

Abstract translation: 公开了用于检测聚集蛋白聚糖-1和/或聚集蛋白聚糖蛋白聚糖酶-2活性的生物标志物。 生物标志物是α2巨球蛋白的特异性肽片段。

公开(公告)号：WO2005047328A2

公开(公告)日：2005-05-26

申请号：PCT/US2004038634

申请日：2004-11-08

Applicant: CURAGEN CORP ,  GULSHAN ARA ,  CHUI DANIEL ,  LAROCHELLE WILLIAM J ,  GALLO MICHAEL L ,  ZHONG HAIHONG

Inventor： GULSHAN ARA ,  CHUI DANIEL ,  LAROCHELLE WILLIAM J ,  GALLO MICHAEL L ,  ZHONG HAIHONG

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K16/18 ,  C07K16/00 ,  C12N5/10 ,  C12N15/13 ,  C12N15/63

CPC classification number: C07K16/3069 ,  A01K2217/075 ,  A61K2039/505 ,  C07K16/38 ,  C07K2317/21 ,  C07K2317/73

Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against secretory leukocyte protease inhibitor (SLPI) and antigen binding fragments thereof. Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules are provided. The invention provides antibodies and antigen-binding fragments thereof specifically bind to SLPI; act to neutralize SLPI activity; and can modulate SLPI effects.

Abstract translation: 根据本发明，提供了针对分泌性白细胞蛋白酶抑制剂（SLPI）的完全人类单克隆抗体及其抗原结合片段。 提供了编码核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列。 本发明提供了与SLPI特异性结合的抗体及其抗原结合片段; 采取措施中和SLPI活动; 并可以调节SLPI效果。

公开(公告)号：WO03053921A9

公开(公告)日：2004-05-13

申请号：PCT/US0222822

申请日：2002-07-18

Applicant: AMERICAN NAT RED CROSS ,  WYETH CORP ,  LAWRENCE DANIEL A ,  GORLATOVA NATALIA ,  CRANDALL DAVID L

Inventor： LAWRENCE DANIEL A ,  GORLATOVA NATALIA ,  CRANDALL DAVID L

IPC: G01N33/50 ,  A61K45/00 ,  A61P43/00 ,  C07K14/81 ,  C07K16/38 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/48 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/37 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566 ,  C07D

CPC classification number: C07K14/8121 ,  C07K14/81 ,  C07K14/8132 ,  C07K16/38 ,  C12Q1/37 ,  G01N2333/81 ,  G01N2500/04

Abstract: A library of mutants of metastable proteins, such as proteinase inhibitors, can be screened for the specific loss of a wild-type capability to bind an antibody, yielding valuable drug-design information which otherwise is unavailable. By this approach, for example, a mutant proteinase inhibitor can be obtained that has the amino acid sequence of a wild-type protein, or an active fragment therof, save for the presence of one or more mutations in at least one epitope, thereby altering interaction of the mutant with an anti-proteinase inhibitor antibody.

Abstract translation: 可以筛选亚稳态蛋白质突变体的文库，例如蛋白酶抑制剂，以便特异性丧失结合抗体的野生型能力，产生否则不可用的有价值的药物设计信息。 通过该方法，例如，可以获得具有野生型蛋白质的氨基酸序列或活性片段的突变蛋白酶抑制剂，除了在至少一个表位中存在一个或多个突变，从而改变 突变体与抗蛋白酶抑制剂抗体的相互作用。

公开(公告)号：WO0233089A3

公开(公告)日：2004-02-26

申请号：PCT/US0142472

申请日：2001-10-05

Applicant: US GOV HEALTH & HUMAN SERV ,  FRANCISCHETTI IVO M B ,  VALENZUELA JESUS G ,  RIBEIRO JOSE M

Inventor： FRANCISCHETTI IVO M B ,  VALENZUELA JESUS G ,  RIBEIRO JOSE M

IPC: A61K38/00 ,  A61K39/00 ,  A61P7/02 ,  A61P9/00 ,  A61P35/04 ,  C07K14/81 ,  C12N1/21 ,  C12N15/15 ,  A61K31/7088 ,  A61K38/57 ,  C07K16/38 ,  C12N5/10 ,  C12N9/64 ,  G01N33/68

CPC classification number: C07K14/8114 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/53

Abstract: Ixolaris, a novel protein with anticoagulant activity is described. Ixolaris can be isolated from the salivary glands of ticks or made by recombinant methods using various DNA expression techniques.

Abstract translation: 描述了具有抗凝活性的新型蛋白质Ixolaris。 Ixolaris可以从蜱的唾液腺分离或通过使用各种DNA表达技术的重组方法制备。

公开(公告)号：WO03046003A3

公开(公告)日：2003-09-04

申请号：PCT/CA0201642

申请日：2002-10-31

Applicant: SYN X PHARMA INC

Inventor： JACKOWSKI GEORGE ,  MARSHALL JOHN

IPC: G01N27/62 ,  A61K38/00 ,  C07K14/47 ,  C07K14/81 ,  C07K16/40 ,  C12N9/50 ,  C12P21/08 ,  C12Q1/37 ,  C12Q1/70 ,  G01N27/64 ,  G01N33/53 ,  G01N33/68 ,  A61K38/17 ,  C07K16/38

CPC classification number: C07K14/8121 ,  A61K38/00 ,  C07K14/4711 ,  G01N33/6896 ,  G01N2800/2821

Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-fl ight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

Abstract translation: 本发明涉及使用组合的准备步骤与质谱法和时间检测程序的组合，以最大化在特定样品中可验证的生物聚合物的多样性。 然后，在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在的能力，以相对于识别所述生物聚合物的存在和/或不存在，预测疾病风险评估以及开发针对所述疾病的治疗途径。

公开(公告)号：WO0069891A9

公开(公告)日：2002-07-04

申请号：PCT/US0013215

申请日：2000-05-15

Applicant: DEPT OF THE ARMY ,  GORDON RICHARD K ,  MOORAD DEBORAH R ,  DOCTOR BHUPENDRA P ,  GARCIA GREGORY E

Inventor： GORDON RICHARD K ,  MOORAD DEBORAH R ,  DOCTOR BHUPENDRA P ,  GARCIA GREGORY E

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/55 ,  A61P31/04 ,  A61P39/02 ,  A61P43/00 ,  C07K7/06 ,  C07K7/08 ,  C07K7/22 ,  C07K11/00 ,  C07K14/81 ,  C07K16/38 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  G01N33/569 ,  A61K38/08 ,  A61K38/57 ,  C12N15/11 ,  G01N33/68

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K7/08 ,  C07K7/22 ,  C07K14/8146

Abstract: The compounds of the invention are generally described by the formula: (1): B1Z 2B3Z 4X 5Q6F7X8X9X10X11, (2): B1X2X3X4X5Q6F7X8X9X10X11, or (3): B1X2B3X4Z5Q6F7Z8X9X10X11 and the salts, esters, amides, and acyl forms thereof. Each position represented by a letter indicates a single amino acid residue: B is a basic or polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X is a small or polar/large amino acid or a modified form thereof; Z is a polar/large or hydrophobic amino acid or a modified form thereof; Z is Proline or a polar/large or hydrophobic amino acid or a modified form thereof. As described below, one or more of the peptide linkages between the amino acid residues may be replaced by a peptide linkage mimic. These compounds may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins.

Abstract translation: 本发明的化合物通常由下式表示：（1）：B1Z * 2B3Z * 4X * 5Q6F7X8X9X10X11，（2）：B1X2X3X4X5Q6F7X8X9X10X11或（3）：B1X2B3X4Z5Q6F7Z8X9X10X11及其盐，酯，酰胺， 及其酰基形式。 由字母表示的每个位置表示单个氨基酸残基：B是碱性或极性/大氨基酸或其修饰形式; X是小或疏水性氨基酸或其修饰形式; X *是小或极性/大的氨基酸或其修饰形式; Z是极性/大或疏水性氨基酸或其修饰形式; Z *是脯氨酸或极性/大或疏水性氨基酸或其修饰形式。 如下所述，氨基酸残基之间的一个或多个肽键可以被肽键模拟物代替。 这些化合物可用作分子结构单元以产生针对抑制肉毒杆菌B和破伤风毒素的蛋白酶活性而优化的化合物。

公开(公告)号：WO02033089A2

公开(公告)日：2002-04-25

申请号：PCT/US2001/042472

申请日：2001-10-05

IPC: A61K38/00 ,  A61K39/00 ,  A61P7/02 ,  A61P9/00 ,  A61P35/04 ,  C07K14/81 ,  C12N1/21 ,  C12N15/15 ,  A61K38/57 ,  A61K31/7088 ,  C12N5/10 ,  C07K16/38 ,  C12N9/64 ,  G01N33/68

CPC classification number: C07K14/8114 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/53 ,  Y02A50/401

Abstract: Ixolaris, a novel protein with anticoagulant activity is described. Ixolaris can be isolated from the salivary glands of ticks or made by recombinant methods using various DNA expression techniques.

Abstract translation: 描述了具有抗凝活性的新型蛋白质Ixolaris。 Ixolaris可以从蜱的唾液腺分离或通过使用各种DNA表达技术的重组方法制备。